Posted by & filed under Economic Analysis, Market Analysis.

Description: Mylan, the maker of the allergy treatment EpiPen, said Friday that it had reached a $465 million settlement with the Justice Department and other government agencies over questions on whether the company had overcharged Medicaid for the treatment by improperly classifying it as a generic drug.


Date: Oct 08, 2016


Questions for discussion:

  • What does the report say about Mylan’s practices and the settlement announced?
  • Do you believe there was no wrongdoing?
  • How should shareholders deal with management of the firm?

Leave a Reply

Your email address will not be published. Required fields are marked *